KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Enterprise Value (2018 - 2025)

Vir Biotechnology's Enterprise Value history spans 8 years, with the latest figure at -$460.9 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 102.79% year-over-year to -$460.9 million; the TTM value through Dec 2025 reached -$460.9 million, down 102.79%, while the annual FY2025 figure was -$460.9 million, 102.79% down from the prior year.
  • Enterprise Value for Q4 2025 was -$460.9 million at Vir Biotechnology, down from -$218.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$61.7 million in Q3 2021 and bottomed at -$2.4 billion in Q4 2022.
  • The 5-year median for Enterprise Value is -$700.1 million (2021), against an average of -$954.7 million.
  • The largest annual shift saw Enterprise Value tumbled 3667.8% in 2022 before it soared 83.57% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$225.8 million in 2021, then tumbled by 949.78% to -$2.4 billion in 2022, then skyrocketed by 45.82% to -$1.3 billion in 2023, then surged by 82.3% to -$227.3 million in 2024, then tumbled by 102.79% to -$460.9 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Enterprise Value are -$460.9 million (Q4 2025), -$218.4 million (Q2 2025), and -$227.3 million (Q4 2024).